ArticleCase reports in hematology2025
Second Primary Malignancy in Ixazomib Maintenance Therapy for Multiple Myeloma: Case Report and Literature Review.
Article in Case reports in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: With the prolongation of life expectancy among multiple myeloma (MM) patients, the development of second primary malignancies (SPMs) has emerged as a serious issue, so it is worthwhile to explore the mechanisms and therapeutic strategy regarding SPMs secondary to MM. Case report: We describe a patient with MM who developed secondary myelodysplastic syndrome (MDS) after 5 years of maintenance chemotherapy with ixazomib. Discussion: In our case, the patient was young and did not have a cytogenetic examination; after a maintenance therapy with ixazomib for about 5 years, he developed the MDS. He was subsequently recommended for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and remains alive. Conclusions: The possibility of an association between ixazomib maintenance treatment and increased SPMs cannot be excluded, requiring future studies with large samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.